Home>Corporate>Milestones

Milestones

  • 1994

    Founded in 1994

  • 1998

    600196.SH

    A-Share listed
    on Shanghai Stock Exchange

  • 2002-2004

    Entered pharmaceutical
    manufacturing field

    China’s No.001 New Drug:
    Artesunate

    Saved more than 30 million lives
    of severe malaria patients

  • 2003

    01099.HK

    Entered pharmaceutical distribution and retail business:
    Jointly established Sinopharm Group with the China National Pharmaceutical Group Corporation.

  • 2009

    Innovation and R&D milestones

  • 2012

    02196.HK

    H-Share listed on Hong Kong Stock Exchange
    Accelerated Internationalization

  • 2013

    1st overseas M&A

  • 2017
    Promote international cooperation

    Jointly established Fosun Kite
    with Kite Pharma

    Jointly established Intuitive Fosun
    with Intuitive Surgical

  • 2018
    01696.HK

    Sisram Medical：

    1st Israeli company listed on HKEx

    Gland Pharma：

    India's first injection drug company with U.S. FDA approval

  • 2019
    02696.HK

    Henlius H-Share listed on Hong Kong Stock Exchange

    1st Biosimilar in China

    Entered Stem Cell Therapeutics field

  • 2020

    Collaborated with BioNTech

    Entered into the mRNA field

    A number of innovative products
    have been approved for marketing

  • The HLX01 (rituximab injection) of Shanghai Henlius approved for marketing at the beginning of 2019, becoming the first biosimilar drug in China.

    The HLX01 (rituximab injection) of Shanghai Henlius approved for marketing at the beginning of 2019, becoming the first biosimilar drug in China.

  • FCN-159 tablet, a new drug of a subsidiary of Fosun Pharma, was approved by the State Food and Drug Administration for clinical trials of advanced solid tumors.

    FCN-159 tablet, a new drug of a subsidiary of Fosun Pharma, was approved by the State Food and Drug Administration for clinical trials of advanced solid tumors.

  • Fosun Pharma cooperated with Marubeni to develop the third-party healthcare market.

    Fosun Pharma cooperated with Marubeni to develop the third-party healthcare market.

  • Fosun Pharma invested US$106 million in Butterfly Network, Inc., for development of smartphone ultrasound imager.

    Fosun Pharma invested US$106 million in Butterfly Network, Inc., for development of smartphone ultrasound imager.

  • SPAQ-CO® Disp, a malaria prevention drug for children of Fosun Pharma, was pre-certified by the World Health Organization.

    SPAQ-CO® Disp, a malaria prevention drug for children of Fosun Pharma, was pre-certified by the World Health Organization.

    Fosun Pharma被認定為上海市企業技術中心

    2011年

    Fosun Pharma獲上海普陀區科技系統先進基層黨組織獎項

    1998-2000年

    Fosun Pharma獲創稅千萬元企業獎項

    1999年

    Fosun Pharma獲1999年中證亞商中國最具發展潛力上市50強企業獎

    1999年7月

    Fosun Pharma獲普陀區先進黨組織獎

    2000年